Drug Costing $9,200 Scores Zero on Cancer Doctor Value Scale

Updated on

The leading group of U.S. cancer doctors created a scoring system for oncology drugs, awarding a zero for overall benefit to the $9,200-a-month regimen featuring Eli Lilly & Co.’s Alimta.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.